Cargando…

The economic burden of visual impairment and blindness: a systematic review

OBJECTIVES: Visual impairment and blindness (VI&B) cause a considerable and increasing economic burden in all high-income countries due to population ageing. Thus, we conducted a review of the literature to better understand all relevant costs associated with VI&B and to develop a multipersp...

Descripción completa

Detalles Bibliográficos
Autores principales: Köberlein, Juliane, Beifus, Karolina, Schaffert, Corinna, Finger, Robert P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822298/
https://www.ncbi.nlm.nih.gov/pubmed/24202057
http://dx.doi.org/10.1136/bmjopen-2013-003471
_version_ 1782290393057984512
author Köberlein, Juliane
Beifus, Karolina
Schaffert, Corinna
Finger, Robert P
author_facet Köberlein, Juliane
Beifus, Karolina
Schaffert, Corinna
Finger, Robert P
author_sort Köberlein, Juliane
collection PubMed
description OBJECTIVES: Visual impairment and blindness (VI&B) cause a considerable and increasing economic burden in all high-income countries due to population ageing. Thus, we conducted a review of the literature to better understand all relevant costs associated with VI&B and to develop a multiperspective overview. DESIGN: Systematic review: Two independent reviewers searched the relevant literature and assessed the studies for inclusion and exclusion criteria as well as quality. ELIGIBILITY CRITERIA FOR INCLUDED STUDIES: Interventional, non-interventional and cost of illness studies, conducted prior to May 2012, investigating direct and indirect costs as well as intangible effects related to visual impairment and blindness were included. METHODS: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement approach to identify the relevant studies. A meta-analysis was not performed due to the variability of the reported cost categories and varying definition of visual impairment. RESULTS: A total of 22 studies were included. Hospitalisation and use of medical services around diagnosis and treatment at the onset of VI&B were the largest contributor to direct medical costs. The mean annual expenses per patient were found to be US$ purchasing power parities (PPP) 12 175–14 029 for moderate visual impairment, US$ PPP 13 154–16 321 for severe visual impairment and US$ PPP 14 882–24 180 for blindness, almost twofold the costs for non-blind patients. Informal care was the major contributor to other direct costs, with the time spent by caregivers increasing from 5.8 h/week (or US$ PPP 263) for persons with vision >20/32 up to 94.1 h/week (or US$ PPP 55 062) for persons with vision ≤20/250. VI&B caused considerable indirect costs due to productivity losses, premature mortality and dead-weight losses. CONCLUSIONS: VI&B cause a considerable economic burden for affected persons, their caregivers and society at large, which increases with the degree of visual impairment. This review provides insight into the distribution of costs and the economic impact of VI&B.
format Online
Article
Text
id pubmed-3822298
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-38222982013-11-12 The economic burden of visual impairment and blindness: a systematic review Köberlein, Juliane Beifus, Karolina Schaffert, Corinna Finger, Robert P BMJ Open Ophthalmology OBJECTIVES: Visual impairment and blindness (VI&B) cause a considerable and increasing economic burden in all high-income countries due to population ageing. Thus, we conducted a review of the literature to better understand all relevant costs associated with VI&B and to develop a multiperspective overview. DESIGN: Systematic review: Two independent reviewers searched the relevant literature and assessed the studies for inclusion and exclusion criteria as well as quality. ELIGIBILITY CRITERIA FOR INCLUDED STUDIES: Interventional, non-interventional and cost of illness studies, conducted prior to May 2012, investigating direct and indirect costs as well as intangible effects related to visual impairment and blindness were included. METHODS: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement approach to identify the relevant studies. A meta-analysis was not performed due to the variability of the reported cost categories and varying definition of visual impairment. RESULTS: A total of 22 studies were included. Hospitalisation and use of medical services around diagnosis and treatment at the onset of VI&B were the largest contributor to direct medical costs. The mean annual expenses per patient were found to be US$ purchasing power parities (PPP) 12 175–14 029 for moderate visual impairment, US$ PPP 13 154–16 321 for severe visual impairment and US$ PPP 14 882–24 180 for blindness, almost twofold the costs for non-blind patients. Informal care was the major contributor to other direct costs, with the time spent by caregivers increasing from 5.8 h/week (or US$ PPP 263) for persons with vision >20/32 up to 94.1 h/week (or US$ PPP 55 062) for persons with vision ≤20/250. VI&B caused considerable indirect costs due to productivity losses, premature mortality and dead-weight losses. CONCLUSIONS: VI&B cause a considerable economic burden for affected persons, their caregivers and society at large, which increases with the degree of visual impairment. This review provides insight into the distribution of costs and the economic impact of VI&B. BMJ Publishing Group 2013-11-06 /pmc/articles/PMC3822298/ /pubmed/24202057 http://dx.doi.org/10.1136/bmjopen-2013-003471 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Ophthalmology
Köberlein, Juliane
Beifus, Karolina
Schaffert, Corinna
Finger, Robert P
The economic burden of visual impairment and blindness: a systematic review
title The economic burden of visual impairment and blindness: a systematic review
title_full The economic burden of visual impairment and blindness: a systematic review
title_fullStr The economic burden of visual impairment and blindness: a systematic review
title_full_unstemmed The economic burden of visual impairment and blindness: a systematic review
title_short The economic burden of visual impairment and blindness: a systematic review
title_sort economic burden of visual impairment and blindness: a systematic review
topic Ophthalmology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822298/
https://www.ncbi.nlm.nih.gov/pubmed/24202057
http://dx.doi.org/10.1136/bmjopen-2013-003471
work_keys_str_mv AT koberleinjuliane theeconomicburdenofvisualimpairmentandblindnessasystematicreview
AT beifuskarolina theeconomicburdenofvisualimpairmentandblindnessasystematicreview
AT schaffertcorinna theeconomicburdenofvisualimpairmentandblindnessasystematicreview
AT fingerrobertp theeconomicburdenofvisualimpairmentandblindnessasystematicreview
AT koberleinjuliane economicburdenofvisualimpairmentandblindnessasystematicreview
AT beifuskarolina economicburdenofvisualimpairmentandblindnessasystematicreview
AT schaffertcorinna economicburdenofvisualimpairmentandblindnessasystematicreview
AT fingerrobertp economicburdenofvisualimpairmentandblindnessasystematicreview